WINDLAS BIOTECH
|
The Current P/E Ratio of WINDLAS BIOTECH is 25.32.
| Share Price | ₹817.0 | May 27,2026 |
| Market Cap | ₹1,682.9 Cr | |
| Earnings-TTM | ₹66.5 Cr | TTM-Consolidated Results |
| Price/Earnings | 25.32x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of WINDLAS BIOTECH
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,682.9 Cr] as on May 27,2026
(/) Earnings [ ₹66.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 25.32x ]
Thus, for WINDLAS BIOTECH , the investors are currently willing to pay 25.32 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of WINDLAS BIOTECH !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of WINDLAS BIOTECH over the last five years.
Historical PE (Price/Earnings) ratio chart of WINDLAS BIOTECH
PE Ratio Performance Analysis for WINDLAS BIOTECH
- WINDLAS BIOTECH 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 15.43x.
- WINDLAS BIOTECH 's operated at median p/e ratio of 12.02x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, WINDLAS BIOTECH 's p/e ratio peaked in Mar2025 at 35.78x.
- WINDLAS BIOTECH 's p/e ratio hit its five-year low in Mar2021 of 0x.
How does WINDLAS BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| WINDLAS BIOTECH | 66.46 | 25.32 | 1,682.9 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 38.28 | 442,677.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 70.27 | 180,458.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 71.88 | 153,685.0 |
| CIPLA LTD | 3,869.79 | 29.60 | 114,562.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 26.57 | 110,095.0 |
| MANKIND PHARMA LTD | 1,926.41 | 51.89 | 99,957.1 |
| LUPIN LTD | 5,355.47 | 19.44 | 104,097.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 21.74 | 109,272.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 23.59 | 82,604.1 |
| LAURUS LABS LTD | 889.85 | 83.79 | 74,562.3 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs WINDLAS BIOTECH 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 19.44x |
| Max industry PE | 83.79x |
| Median industry PE | 29.60x |
| Average industry PE | 42.03x |
You may also like the below Video Courses